
EOCN P/E Ratio
P/E Ratio as of Sep 10, 2026: -0.29
Average-0.2927
Median-0.2850
Minimum-0.3500
Maximum-0.2500
-0.29
0.05 (14.71%)past month
The P/E ratio for EOCN is -0.29 as of Sep 10, 2026. This represents a decrease of -12.12% compared to its 12-month average P/E ratio of -0.33. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Galmed Pharmaceuticals Ltd P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Galmed Pharmaceuticals Ltd’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Galmed Pharmaceuticals Ltd to industry peers.
Galmed Pharmaceuticals Ltd P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Galmed Pharmaceuticals Ltd’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Galmed Pharmaceuticals Ltd to industry peers.
EOCN P/E Ratio Insights
See Galmed Pharmaceuticals Ltd’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in EOCN
Order type
Buy in
Order amount
Est. shares
0 shares
EOCN P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Sep 1, 2026 | $3.925 | -0.28 |
| Aug 3, 2026 | $4.68 | -0.34 |
| Jul 1, 2026 | $5.1824 | -0.38 |
| Jun 1, 2026 | $5.8176 | -0.36 |
| May 1, 2026 | $4.5688 | -0.29 |
| Apr 1, 2026 | $4.24 | -0.26 |
| Mar 2, 2026 | $4.94 | -0.26 |
| Feb 2, 2026 | $5.3232 | -0.29 |
| Jan 2, 2026 | $6.5832 | -0.35 |
EOCN End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | -0.29 | -9.38% |
| 2025 | -0.32 | -8.57% |
| 2024 | -0.35 | +191.67% |
| 2023 | -0.12 | -78.18% |
| 2022 | -0.55 | -60.14% |
| 2021 | -1.38 | — |
FAQs About Galmed Pharmaceuticals Ltd (EOCN) P/E ratio
The latest P/E ratio of EOCN is -0.29, as of Sep 10, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Galmed Pharmaceuticals Ltd’s last 12-month average P/E ratio is -0.33, compared to its current P/E ratio of -0.29. This reflects a decrease of -12.12%.
Galmed Pharmaceuticals Ltd’s current P/E ratio of -0.29 is lower than its last 12-month average P/E of -0.33. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Galmed Pharmaceuticals Ltd’s average P/E ratio over the last 3 years is -0.26. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Galmed Pharmaceuticals Ltd’s average P/E ratio over the last 5 years is -0.49. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.